Primary Dysmenorrhea
Conditions
Keywords
dysmenorrhoea, dysmenorrhea, pain, pre-emptive
Brief summary
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
Detailed description
Dysmenorrhoea is suffered by between 50% and 90% of women of child bearing age. Up to 30% of these women are non-responsive to the currently prescribed therapies. As such it represents an area of unmet medical need. VA111913 inhibits vasopressin-induced contractions of human myometrial strips and human myometrial blood vessels in vitro. By this mechanism, it is anticipated that the pain of dysmenorrhoea, a condition in which myometrial tone and contractions are increased and blood flow to the uterus is decreased compared to normal, may be reduced. Subjects will be dosed with VA111913 TS and placebo in a cross over design during two consecutive menstrual cycles. They will be dosed for up to a maximum of 6 days, beginning 2 days before the onset of menstruation. Subjects will then assess the menstrual pain, bleeding and amount of analgesia required to treat symptoms during each cycle
Interventions
DRUGVA111913 TS and placebo
VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
Sponsors
Vantia Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Women between 18 and 35 years old * Not pregnant * History of primary dysmenorrhoea * Regular menstrual cycles * Signed informed consent
Exclusion criteria
* Known secondary dysmenorrhoea * Concomitant use of regular prescription or non prescription medications or herbal remedies * Any clinically significant medical history or active disease * Participation in another clinical study in the last 3 months * Contraindication to chosen rescue medications or allergy to their constituents * Other protocol defined eligibility criteria may apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain assessed using standard scoring system | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Safety assessed by laboratory findings, vital signs, ECGs and AEs | 3 months |
| Assessment of treatment effectiveness | 3 months |
| Requirement for rescue medication | 3 months |
| Assessment of menstrual bleeding | 3 months |
| PK assessments | 3 months |
Countries
United Kingdom, United States
Outcome results
None listed